Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$7.65 USD
-0.24 (-3.04%)
Updated Apr 17, 2024 03:59 PM ET
After-Market: $7.52 -0.13 (-1.70%) 5:54 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.65 USD
-0.24 (-3.04%)
Updated Apr 17, 2024 03:59 PM ET
After-Market: $7.52 -0.13 (-1.70%) 5:54 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Zacks News
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.
Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.
What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?
by Zacks Equity Research
Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.
DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.
Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA
by Zacks Equity Research
The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.
Minerva (NERV) Soars on Promising Schizophrenia Study Data
by Zacks Equity Research
Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.
Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.
Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD)
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations. Stock down.
Ironwood Pharmaceuticals (IRWD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 9.09% and 3.82%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.
Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.
Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.